跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT06371040
NCT06371040招募中1 期

Evaluate the Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory, Generalized Myasthenia Gravis: A Single-center, Open-label, Single-arm, Dose-finding Study

Ting Chang, MD1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2024年7月12日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
9
试验地点
1
主要终点
Frequency, type, and severity of adverse events
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of CD19-BCMA CAR-T in the treatment of refractory, generalized myasthenia gravis. The study is a dose escalation trial in adult, refractory, systemic MG patients. The Keyboard method will be used to perform dose escalation to explore the maximum tolerated dose (MTD). A total of 12 MG patients who meet the inclusion criteria are expected to be recruited.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Study participants will be selected for this study only if they meet all of the following criteria:
  • •Age ≥18 years old and ≤80 years old;
  • •The subject signs the informed consent form, is willing and able to comply with the protocol, complete the research assessment and return for follow-up;
  • •To be diagnosed as a patient with systemic MG, the patient is required to have positive myasthenia-related antibodies (AChR-Ab, Musk-Ab or LRP4) on the basis of typical myasthenic symptoms;
  • •Evaluated by the researcher as refractory MG. Refractory MG is defined as:
  • •Treatment failed after receiving at least 2 immunosuppressants
  • •Definition of treatment failure: 1) Persistent weakness and impairment of daily activities; 2) MG aggravation and/or crisis during treatment; 3) Intolerance to immunotherapy due to side effects or comorbidities;
  • •Repeated plasma exchange (PE) or intravenous immune globulin (IVIg) treatment is required to control symptoms;
  • •The researchers believe that despite the current routine immunotherapy for patients, MG still imposes a large functional burden on patients.
  • •MGFA classification IIa~IVa at screening and baseline;
  • •QMGS score ≥11 points or MG-ADL score ≥5 points at screening and baseline, of which the eye score accounts for no more than 50%;
  • •Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;
  • •If you are a woman of childbearing potential (WOCBP), you must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CART for the first time.

排除标准

  • •Prior to screening and the baseline visit, study participants will not be eligible for inclusion in the study if they meet any of the following criteria:
  • •The researcher believes that there is any medical or mental condition that may harm the research participant or affect the research participant's ability to participate in this study; or any condition that the researcher believes is related to poor compliance;
  • •Women who are lactating or pregnant, or women who plan to become pregnant at any time within 12 months after receiving CART treatment, or who have a history of spontaneous abortion or induced abortion within 4 weeks before screening;
  • •Study participants have clinically relevant active infections (such as sepsis, pneumonia or abscess) or serious infections (resulting in hospitalization or requiring antibiotic treatment) within 4 weeks before screening;
  • •thymoma that underwent thymectomy within 6 months before baseline or was planned to undergo thymectomy during the study, or required chemotherapy and/or radiotherapy at any time;
  • •Investigator participants have received live attenuated vaccine vaccination within 8 weeks before screening; or plan to receive live vaccine vaccination within 8 weeks after treatment;
  • •Study participants have received rituximab treatment within 6 months before screening;
  • •Have received tocilizumab or eculizumab treatment within 3 months before screening;
  • •Have received intravenous human immunoglobulin, plasma exchange, or immunotherapy within 4 weeks before screening;
  • •Those with known serious underlying diseases, such as liver and kidney damage, blood diseases, previous severe cardiovascular disease, severe hypertension, diabetes, and poor blood pressure and blood sugar control;
  • •Unresected thymoma (Note: Subjects with benign thymoma resected more than one year before screening are eligible. Benign is defined as no known metastasis on pathological examination and no intracystic or extracystic Extension. Imaging studies must be performed during the screening period to assess thymic status).
  • •Any of the following laboratory abnormalities occur during the screening period (one repeat measurement can be performed during the screening period before randomization to confirm the results)
  • •Elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN)).
  • •Total bilirubin>1.5 times ULN
  • •Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
  • •Abnormal PT or INR, or prolonged APTT >1.5 times ULN
  • •Neutrophil count <1000cell/ul
  • •Platelet count <50000/mm3
  • •Hemoglobin<8.0g/dl
  • •Those with a high-risk history of tuberculosis infection or acquired tuberculosis infection;
  • •Known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection;
  • •Positive for hepatitis B surface antigen (HBsAg) during the screening period;
  • •Receive blood transfusion treatment 4 weeks before screening or during the screening period;
  • •Symptoms worsen rapidly during the lead-in period and enter crisis or pre-crisis state (MGFA IVb-V)
  • •Other circumstances in which the researcher deems it inappropriate to participate in the study.

研究组 & 干预措施

CD19-BCMA Targeted CAR-T

Experimental

干预措施: CD19-BCMA Targeted CAR-T Dose 1 (Drug)

CD19-BCMA Targeted CAR-T

Experimental

干预措施: CD19-BCMA Targeted CAR-T Dose 2 (Drug)

结局指标

主要结局

Frequency, type, and severity of adverse events

时间窗: From Baseline (Day 1) to Safety Follow-Up Visit (up to 4 weeks)

Frequency, type, and severity of adverse events (according to the National Cancer Institute Common Terminology Criteria for Adverse Events CTCAE V5.0) occurring within 4 weeks after CD19-BCMA CAR-T infusion

次要结局

  • Changes of Myasthenia Gravis Composite (MGC) scores(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Changes of Myasthenia Gravis Activities of Daily Living (MG-ADL) scores(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Changes of blood pressure(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Changes of pulse rate(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Changes of weight(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Frequency, type, and severity of abnormal laboratory indicators related to treatment(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Time to achieve clinical improvement(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Changes of myasthenia gravis-specific autoantibody titers(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Changes of Quantitative Myasthenia Gravis (QMG) scores(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Changes of immunoglobulins(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))
  • Proportion of subjects who achieved improvement(From Baseline (Day 1) up fo Follow-Up (up to 24 weeks))

研究者

发起方
Ting Chang, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ting Chang, MD

Associate Professor

Tang-Du Hospital

研究点 (1)

Loading locations...

相似试验

Unknown
不适用
C-CAR011 Treatment in Subjects With ALL After HSCTAcute Lymphoblastic Leukemia(ALL)
NCT03327285Peking University People's Hospital40
Unknown
1 期
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic LeukemiaRelapsed Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
NCT04012879Chinese PLA General Hospital12
Unknown
1 期
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
NCT04012892Chinese PLA General Hospital12
招募中
1 期
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple MyelomaRelapsedRefractoryMultiple Myeloma
NCT06732232Shanghai Cell Therapy Group Co.,Ltd12
招募中
早期 1 期
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)Non-Hodgkin Lymphoma, B-cell
NCT06446128Shanghai Cell Therapy Group Co.,Ltd20
Safety and Efficacy of CD19-BCMA Targeted CAR-T... | 临床试验